Clinical development is speeding up! Veta-Jay Bo-B (09887.HK) TCE dual antibody phase I efficacy comparable to CAR-T, the first patient successfully treated in phase II.

Wisdom Financial APP learned that on August 25, Weilitzibo-B (09887.HK) announced that the company's independently developed GPRC5D/CD3 bispecific antibody successfully completed phase II clinical research (CTR20232974) with the first patient enrolled, making it the first domestic TCE therapy targeting GPRC5D. This study is a multicenter, single-arm, multi-cohort phase II clinical trial led by Professor Lu Jin of Peking University People's Hospital, with more than 20 hospitals nationwide participating, aiming to evaluate the efficacy and safety of LBL-034 in patients with various relapsed/refractory plasma cell tumors.